Chimerix Acquires Oncoceutics

Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals

December 7, 2021

Pharmaceuticals

Xcovery Holdings, an oncology-focused biopharmaceutical company, has acquired a majority and controlling stake in Meryx, Inc., a clinical-stage immuno-oncology company based in Chapel Hill, North Carolina. The deal aims to accelerate Meryx's clinical and preclinical drug development programs for small-molecule oncology therapies, with strategic support noted from Betta Pharmaceuticals; financial terms were not disclosed.

Merck Acquires OncoImmune

November 23, 2020

Biotechnology

Merck will acquire all outstanding shares of clinical-stage biopharmaceutical OncoImmune for $425 million upfront in cash, with additional sales-based and regulatory milestone payments possible. The deal centers on accelerating development of OncoImmune’s CD24Fc for severe and critical COVID-19; non-CD24Fc assets will be spun out into a new company in which Merck will invest $50 million for a minority stake.

Symeres Acquires Oncolines

January 10, 2023

Healthcare Services

Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.

Amgen Acquires ChemoCentryx

August 4, 2022

Biotechnology

Amgen agreed to acquire ChemoCentryx for $52 per share in cash (approximately $3.7 billion enterprise value), gaining TAVNEOS (avacopan), a first-in-class oral therapy for ANCA-associated vasculitis. The deal, unanimously approved by both boards, is intended to strengthen Amgen's inflammation and nephrology portfolio and is expected to close following stockholder and regulatory approvals.

Framework Solutions Acquires ONIX Life Sciences

March 1, 2023

Healthcare Services

Framework Solutions has acquired UK-based ONIX Life Sciences to expand its regulatory operations and eCTD submission capabilities. The deal strengthens Frameworks' service offerings for life sciences clients and broadens its geographic reach; terms were not disclosed.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.